Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Recurrent small cell lung cancer (SCLC) has limited treatment options, with topotecan as the only approved second-line therapy yielding poor outcomes.
• The CheckMate 032 study investigated nivolumab (alone or with ipilimumab) in previously treated SCLC and other advanced solid tumors.

Purpose of the Study:

• To evaluate the efficacy and safety of third- or later-line nivolumab monotherapy in patients with recurrent SCLC.
• To determine objective response rate, duration of response, progression-free survival, and overall survival.

Main Methods:

• An open-label, multicenter, phase 1/2 study included 109 patients with SCLC progressing after two or more chemotherapy regimens.
• Patients received nivolumab monotherapy (3 mg/kg every 2 weeks) until disease progression or unacceptable toxicity.

Main Results:

• The objective response rate was 11.9% (95% CI: 6.5-19.5), with a median duration of response of 17.9 months.
• 12-month and 18-month overall survival rates were 28.3% and 20.0%, respectively.
• Grade 3-4 treatment-related adverse events occurred in 11.9% of patients, with 2.8% discontinuing treatment.

Conclusions:

• Nivolumab monotherapy demonstrated durable responses and was well-tolerated in the third- or later-line setting for recurrent SCLC.
• These findings suggest nivolumab monotherapy is an effective treatment option for this patient population with advanced SCLC.